Glucagon Receptor Agonist Shows Early Promise in Type 1 Diabetes
Medscape SAN DIEGO — An investigational glucagon receptor agonist — the human antibody REMD-477 (REMD Biotherapeutics) — has shown promise in a 26-day, phase 1 study of patients with type 1 diabetes. Specifically, those who received a single ... |
Social Plugin